new compound
A compound, benzo technology, applied in the field of compounds, can solve problems such as limited effectiveness
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0506] (S)-7-(2-(2-(2-(2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinoline-7- Base)oxy)ethoxy)ethoxy)ethoxy)ethoxy)-2-((S)-3,3-dimethyl-2-((S)-2-(methylamino ) C Amino)butanoyl)-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide, 2 hydrochloric acid Salt
[0507]
[0508] ((S)-1-(((S)-1-((S)-7-(2-(2-(2-(2-((4-(benzo[d]thiazol-5-yl Amino)-6-(tert-butylsulfonyl)quinolin-7-yl)oxy)ethoxy)ethoxy)ethoxy)ethoxy)-3-(((R)-1,2 ,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3,3-dimethyl-1-oxobutanyl- A solution of 2-yl)amino)-1-oxopropan-2-yl)(methyl)carbamate (65 mg, 0.055 mmol) in THF (1.5 mL) was washed with hydrochloric acid (4M at 1, 4-dioxane) (3 mL, 12 mmol) and allowed to stand overnight. The solution was evaporated to dryness and the residual product was subjected to purification by mass controlled automated preparative HPLC (ammonium bicarbonate modifier). The recovered material was di...
Embodiment 2
[0510] (S)-7-(2-(2-(2-(2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinoline-7- Base)oxy)ethoxy)ethoxy)ethoxy)ethoxy)-2-((S)-3,3-dimethyl-2-((S)-2-(methylamino ) C Amino)butanoyl)-N-((S)-1,2,3,4-tetrahydronaphthalen-1-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide, 2 hydrochloric acid Salt
[0511]
[0512] In analogy to (S)-7-(2-(2-(2-(2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinoline -7-yl)oxy)ethoxy)ethoxy)ethoxy)ethoxy)-2-((S)-3,3-dimethyl-2-((S)-2-( Methylamino)propionamido)butanoyl)-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)-1,2,3,4-tetrahydroisoquinoline- 3-carboxamide, 2 hydrochloride (Example 1) using (S)-1,2,3,4-tetrahydronaphthalene-1-amine instead of (R)-1,2,3,4-tetra Hydronaphthalene-1-amine to prepare the title compound. LCMS RT = 0.74 min, ES+ve 1093.
Embodiment 3
[0514] (S)-7-(2-(2-(2-(2-((6-(tert-butylsulfonyl)-4-((4,5-dimethyl-1H-pyrazol-3-yl )ammonia Base) quinazolin-7-yl) oxy) ethoxy) ethoxy) ethoxy) ethoxy) -2-((S)-3,3-dimethyl-2-((S )-2- (Methylamino)propionamido)butanoyl)-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)-1,2,3,4-tetrahydroisoquinoline -3- Formamide, 2 hydrochloride
[0515]
[0516] ((S)-1-(((S)-1-((S)-7-(2-(2-(2-(2-((6-(tert-butylsulfonyl)-4-( (4,5-Dimethyl-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)ethoxy)ethoxy)ethoxy)ethoxy)-3- (((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3,3-di Methyl-1-oxobut-2-yl)amino)-1-oxopropan-2-yl)(methyl)carbamate (380 mg, 0.33 mmol) in dichloromethane (5 mL ) was treated with trifluoroacetic acid (5 mL) and stirred at ambient temperature for 30 min. The mixture was evaporated to dryness; the residue was then dissolved in 4 mL THF and treated with 4M HCl in 1,4-dioxane (5 mL). After 18 hours, the resulting suspension was diluted with d...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


